Waiting for results on XL protocol and instrument...I think revenue will double based on some data and demand that I have seen...My target for April is 5+, and if they can double their profit then it might go to 16 ( ipo level)
We started with one project and now we have seven genome projects using PACB data. I hear similar things from JGI, Broad, WASHU and Sanger institutes. This company has lot of potential and they already demonstrated across multiple projects. PACB is already eating Illumina, 454 and Lifetech's lunch and dinner... This is easily 15+ stock and might be a acquisition target by Illumina, Roche or Lifetech.